The following study has recently been activated for patient enrollment by The University of Illinois Cancer Center Clinical Trials Office (CTO). Click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, email email@example.com or call 312-355-5112.
CBYL719H12301: A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Sponsor: Novartis Pharmaceuticals
Principal Investigator: Kent Hoskins, MD